Quick Answer
Epitalon (AEDG tetrapeptide) targets the pineal gland and is studied primarily for telomerase activation, melatonin restoration and lifespan extension, while pinealon (EDR tripeptide) targets the brain and central nervous system and is studied for neuroprotection, oxidative stress reduction and DNA-promoter-mediated gene regulation. Neither is FDA-approved, and the evidence for both originates primarily from the same St Petersburg research programme.
Comparison Summary
Epitalon and pinealon are both Khavinson bioregulators developed at the St Petersburg Institute of Bioregulation and Gerontology, and both are proposed to modulate gene expression via direct interaction with DNA. Despite these shared origins and the similarity of their names, they target different tissues, operate through different molecular pathways, and have markedly different evidence profiles. The table below summarises the key distinctions.
| Feature | Epitalon | Pinealon |
|---|---|---|
| Sequence | Ala-Glu-Asp-Gly (AEDG) | Glu-Asp-Arg (EDR) |
| Length | Tetrapeptide (4 amino acids) | Tripeptide (3 amino acids) |
| CAS Number | 307297-39-8 | 175175-23-2 |
| Molecular Weight | 390.35 Da | 418.407 Da |
| Derived from | Epithalamin (bovine pineal gland extract) | Cortexin (bovine brain cortex extract) |
| Target tissue | Pineal gland | Brain / central nervous system |
| Primary mechanism | Telomerase activation, melatonin restoration | DNA-promoter interaction, antioxidant gene upregulation, caspase-3 reduction |
| Evidence depth | Broader (20+ years, multiple model organisms, human cell culture telomerase data, primate melatonin data, rodent lifespan data) | Narrower (rodent and cell-culture neuroprotection, fibroblast conversion, no primate or lifespan data) |
| FDA pathway | PCAC review scheduled July 2026 (insomnia) | No PCAC nomination, no FDA pathway |
| Parent drug in Russia | Epithalamin (registered pharmaceutical) | Cortexin (registered pharmaceutical, GEROPHARM) |
| Independent replication | Limited (Ullah 2025 bovine oocyte, Pendina 2019 lymphocyte, Gatta diabetic retinopathy) | None identified outside St Petersburg lineage |
The bottom line: Despite both being Khavinson bioregulators, epitalon and pinealon target different tissues, operate through different pathways, and have different evidence profiles, making them non-interchangeable compounds.
How They Differ: Origin and Identity
The names can mislead. “Pinealon” sounds as though it should derive from the pineal gland, but it does not. Pinealon was identified as a short active peptide sequence within cortexin, a preparation extracted from bovine brain cortex tissue. Cortexin is a registered Russian pharmaceutical manufactured by GEROPHARM, approved for use in stroke, perinatal brain injury and cognitive disorders. The name “pinealon” reflects its proposed effect on pinealocyte function (specifically serotonin synthesis via TPH1 upregulation), not its tissue of origin.
Epitalon, by contrast, is precisely what its name suggests. It is the synthetic active peptide identified within epithalamin, the pineal gland extract that is itself a registered Russian pharmaceutical. Epitalon is the Cytogen (synthetic) version of what epithalamin delivers as a Cytomax (natural extract).
Both compounds sit within the broader Khavinson bioregulator framework, which hypothesises that ultra-short tissue-specific peptides can modulate gene expression by interacting with DNA promoter regions. Both were developed at the St Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson (1946-2024).
The bottom line: Pinealon derives from brain cortex tissue (cortexin), not the pineal gland, while epitalon derives from pineal tissue (epithalamin), and this difference in origin directly shapes their biological targets.
Mechanism Comparison
Both peptides are proposed to enter the cell nucleus and interact with DNA, but they target entirely different biological processes once inside.
Epitalon: Telomerase and Melatonin
Epitalon’s primary studied mechanism is telomerase activation. In human fetal fibroblast cultures, epitalon induced measurable telomerase activity and promoted cell proliferation beyond the Hayflick limit (Khavinson 2003, Bulletin of Experimental Biology and Medicine). In human blood lymphocyte cultures, it increased telomere length by approximately 33% over controls (Pendina 2019). A 2025 study by Ullah et al. independently demonstrated telomerase activation in bovine oocytes.
Epitalon also acts on melatonin synthesis. In a primate model (rhesus macaques), epitalon administration restored age-related melatonin decline (Khavinson 2001), and studies in rat pinealocyte cultures showed direct stimulation of AANAT (arylalkylamine N-acetyltransferase) and the pCREB transcription factor, the enzymatic pathway responsible for melatonin production.
For the full evidence review, including retinal protection, anti-cancer data and lifespan extension findings, see the epitalon guide.
Pinealon: Neuroprotection and Gene Regulation
Pinealon’s mechanism operates on a different axis. The proposed pathway involves nuclear penetration (demonstrated via fluorescence-labelled HeLa cell studies) and binding to specific DNA sequences (d(CCTGCC)₂ and d(CCAGC)₂ motifs), leading to upregulation of antioxidant and neuroprotective genes including SOD2, GPX1, PPARA, PPARG, TPH1 and NES.
The TPH1 (tryptophan hydroxylase 1) upregulation is the most distinctive feature of pinealon’s proposed activity. TPH1 is the rate-limiting enzyme in peripheral serotonin synthesis, and its upregulation (1.9-fold in young brain cortex cell cultures) provides the proposed link to the pineal gland and circadian function, despite pinealon not originating from pineal tissue. Pinealon also reduces caspase-3 expression (the executioner caspase in apoptosis) in aged rodent models under acute hypoxia.
For the full evidence review, including the 5xFAD Alzheimer’s model, prenatal protection data and the Huberman Lab REM sleep discussion, see the pinealon guide.
Molecular-Level Binding Differences
Both peptides are proposed to interact with nuclear structures, but the binding targets identified in molecular modelling and experimental studies are entirely different. A 2020 study (Khavinson, Diomede, Sinjari et al., Molecules) used molecular modelling to predict that epitalon (AEDG) binds preferentially to histone proteins H1/3 and H1/6 at specific amino acid sequences (His-Pro-Ser-Tyr-Met-Ala-His-Pro-Ala-Arg-Lys and Tyr-Arg-Lys-Thr-Gln sites), positioning it to alter chromatin conformation around genes involved in neurogenic differentiation and melatonin synthesis.
Pinealon (EDR), by contrast, has been studied for direct DNA-sequence binding rather than histone binding. Fluorescence-labelled HeLa cell studies demonstrated nuclear penetration, and the proposed binding motifs are specific DNA sequences: d(CCTGCC)₂ and d(CCAGC)₂. This is a structurally different interaction – histone binding versus DNA major groove binding – and it may explain why the two peptides regulate non-overlapping sets of downstream genes despite sharing the same general bioregulator framework.
Gene Expression Profiles Are Non-Overlapping
The downstream gene targets identified for each compound have zero overlap. Epitalon has been shown to upregulate neurogenic differentiation markers (Nestin, GAP43, beta-Tubulin III and Doublecortin) in human gingival mesenchymal stem cells by 1.6-1.8 times, and separately to activate telomerase and AANAT/pCREB in pinealocyte cultures. Pinealon’s identified gene targets are SOD2 and GPX1 (antioxidant defence), PPARA and PPARG (peroxisome proliferator-activated receptors), TPH1 (serotonin synthesis), CASP3 (apoptosis), and NES, GAP43 and APOE (neuroprotection). The only gene name appearing in both lists is GAP43, but the cell types studied were different (gingival MSCs for epitalon, brain cortex cultures for pinealon), and the proposed regulatory mechanisms are distinct.
A useful shorthand: epitalon addresses systemic ageing at the cellular replication level (telomerase, melatonin rhythmicity), while pinealon addresses ageing at the neuronal survival level (antioxidant gene expression, caspase suppression, serotonin pathway). They do not overlap mechanistically despite both being classified as bioregulators.
The bottom line: Epitalon’s studied pathway centres on telomerase activation and melatonin restoration, while pinealon’s centres on DNA-promoter-mediated neuroprotective gene expression, making them complementary rather than competing compounds within the bioregulator framework.
Evidence Comparison
The evidence gap between epitalon and pinealon is substantial. Epitalon has been studied for over 20 years across multiple model organisms, while pinealon’s evidence base is narrower, more recent and limited to cell culture and rodent models.
| Evidence Category | Epitalon | Pinealon |
|---|---|---|
| Human cell culture | Telomerase activation in fibroblasts and lymphocytes (Khavinson 2003, Pendina 2019) | TPH1 upregulation in brain cortex cultures, fibroblast-derived induced neurons (Kraskovskaya 2024) |
| Animal lifespan | 12-13% maximum lifespan extension in SHR mice (n=108); 11-16% in Drosophila | No lifespan studies published |
| Primate data | Melatonin restoration in rhesus macaques (Khavinson 2001) | None |
| Neuroprotection | Not a primary research focus | Caspase-3 reduction in aged rats (Mendzheritskii 2014); 5xFAD Alzheimer’s model (Khavinson 2021); prenatal neuroprotection (Arutjunyan 2012) |
| Retinal / oncology | Campbell rat retinal protection; DMH colon carcinogenesis; HER-2/neu tumour suppression | Not studied in these contexts |
| Independent replication | Limited (Ullah 2025 bovine oocyte, Pendina 2019 lymphocyte, Gatta diabetic retinopathy, plus 2020 Italian MSC collaboration) | None identified outside the St Petersburg lineage |
| Human clinical trials | None (parent drug epithalamin was used in the 266-patient non-randomised mortality study) | None |
Both compounds share a common evidential weakness: the overwhelming concentration of research within the St Petersburg programme. For epitalon, at least four instances of semi-independent data now exist: the Pendina lymphocyte telomere work, the Ullah 2025 bovine oocyte study, the Gatta diabetic retinopathy corroboration, and a 2020 collaboration with the University of Chieti in Italy (Diomede, Sinjari et al., Molecules) that tested epitalon in human gingival mesenchymal stem cells at a Western laboratory. That Italian study confirmed upregulation of neurogenic markers (Nestin, GAP43, beta-Tubulin III, Doublecortin) and modelled specific histone binding sites, providing a type of mechanistic verification that no pinealon study has achieved outside the St Petersburg group. For pinealon, no research published to date falls outside the direct St Petersburg lineage. The Khavinson programme’s own 2020 and 2022 reviews (Linkova, Ilina and Kozhevnikova) are transparent about this limitation.
Of the two compounds, epitalon has the more developed evidence base by a significant margin, with data spanning multiple model organisms, a human cell-culture telomerase finding, and a primate melatonin study. Pinealon’s evidence remains confined to cell culture and rodent neuroprotection models.
One unique data point for pinealon that epitalon lacks is the Huberman Lab discussion (October 2024, Koniver episode), in which a clinician reported subjective doubling of REM sleep over four to six months with pulsed use. This is anecdotal rather than clinical evidence, but it has driven significant search interest and consumer awareness of pinealon specifically. The pinealon guide covers this in detail.
The bottom line: Epitalon’s evidence base is broader and more mature, spanning multiple species and including telomerase data in human cells, while pinealon’s evidence is limited to rodent and cell-culture neuroprotection studies with no independent replication.
Regulatory Status Comparison
Neither epitalon nor pinealon is approved by the FDA, EMA, MHRA or TGA for any indication. However, their regulatory positions differ in important ways.
| Regulatory Dimension | Epitalon | Pinealon |
|---|---|---|
| FDA status | Not approved. Removed from Category 2 list pending PCAC review | Not approved. Never nominated for the 503A Bulks List |
| PCAC review | Scheduled July 24, 2026 (insomnia indication) | Not scheduled |
| RFK reclassification | Affected (removed from Category 2 on April 15, 2026) | Affected (mentioned in broader reclassification context) |
| Russian status | Synthetic analogue of epithalamin (registered pharmaceutical) | Synthetic analogue of cortexin (registered pharmaceutical) |
| WADA status | Not individually named on 2024 Prohibited List | Not listed (no ergogenic mechanism) |
| MHRA / TGA | Not licensed / not approved | Not licensed / not approved |
The most significant regulatory difference is the PCAC pathway. Epitalon has a nominated review for July 2026, giving it a potential (though far from certain) path toward 503A compounding eligibility if the committee rules favourably. Pinealon has no such pathway and is not currently on any regulatory radar in Western jurisdictions. For how the FDA category system works and what the difference between Category 1 and Category 2 means in practice, see the dedicated guide.
For how individual countries regulate peptides more broadly, see our guides for the US, the UK and Australia.
The bottom line: Epitalon has a nominated PCAC review pathway that could lead to 503A compounding eligibility, while pinealon has no Western regulatory pathway at all.
Safety Profile Comparison
Neither compound has undergone formal Phase 1 safety evaluation in a published, peer-reviewed human trial. Safety data for both is drawn from animal toxicology, cell-culture studies and the Russian clinical experience with their parent drugs.
Epitalon’s parent drug, epithalamin, has been used in Russian clinical practice for decades. The 266-patient, 6-to-8-year study reported no significant adverse events. Animal studies in rodents across multiple models have not identified dose-limiting toxicity. However, the absence of formal Western pharmacovigilance means that rare or long-term adverse effects may be undetected.
Pinealon’s parent drug, cortexin, has decades of prescribing history in Russia for neurological indications including stroke, perinatal brain injury and cognitive disorders. The animal data for pinealon specifically includes studies in aged rats under hypoxic stress with no reported adverse events, and neonatal models with no developmental toxicity signals. The same limitations apply: no Western pharmacovigilance, no formal Phase 1 data for the synthetic peptide itself.
The absence of reported adverse events in Russian clinical programmes is not the same as demonstrated safety by FDA standards. Both compounds lack the controlled human safety data that Western regulators require before approving or permitting compounding of any substance.
One theoretical consideration specific to epitalon is the long-term implication of telomerase activation. While telomerase is associated with cellular rejuvenation, uncontrolled telomerase activity is also a hallmark of cancer. The animal studies (including the DMH colon carcinogenesis model) did not show increased tumour incidence, but the question of whether chronic telomerase activation could promote malignancy over very long periods remains unanswered. This concern does not apply to pinealon, which does not activate telomerase.
When evaluating either compound’s source material, always verify the certificate of analysis for identity, purity and contaminant testing.
The bottom line: Both compounds have decades of parent-drug use in Russian clinical practice without reported safety signals, but neither has formal Phase 1 human safety data by Western standards, and epitalon carries a theoretical long-term question around telomerase activation and cancer risk that pinealon does not share.
Frequently Asked Questions
Is pinealon a pineal gland peptide?
No. Despite the name, pinealon was extracted from brain cortex tissue via the parent drug cortexin, not from the pineal gland. It is named for its proposed effect on pinealocyte function (through TPH1/serotonin upregulation), not its tissue of origin. Epitalon is the bioregulator actually derived from pineal tissue (via epithalamin).
Do epitalon and pinealon work on the same biological pathway?
No. Both are proposed to interact with DNA, but they target completely different genes and processes. Epitalon’s studied pathway centres on telomerase activation and melatonin synthesis (via AANAT/pCREB). Pinealon’s studied pathway centres on antioxidant gene upregulation (SOD2, GPX1), serotonin synthesis (TPH1) and anti-apoptotic effects (caspase-3 reduction). They share the general bioregulator mechanism framework but operate on different molecular axes.
Which has more evidence?
Epitalon has significantly more evidence. It has been studied for over 20 years across human cell cultures, rodent models, Drosophila and primates, with multiple endpoints (telomerase, melatonin, retinal protection, anti-cancer, lifespan extension). Pinealon’s published evidence is limited to rodent neuroprotection studies and cell culture work, with no lifespan, primate or non-Russian replication data. Both share the fundamental weakness of evidence concentration within a single research programme.
Can epitalon and pinealon be used together?
The Khavinson research programme has studied epitalon and pinealon as companion compounds in some contexts (the 5xFAD Alzheimer’s model used pinealon alongside the tripeptide KED). However, no controlled study has evaluated the specific epitalon-plus-pinealon combination in any model. Because they target different pathways (telomerase/melatonin versus neuroprotective gene regulation), there is no known pharmacological interaction between them, but the absence of interaction data is not the same as confirmed safety of the combination.
Which compound affects sleep?
Both have proposed connections to sleep, but through different mechanisms. Epitalon restores melatonin production (demonstrated in primate and pinealocyte culture studies), which regulates circadian timing and sleep onset. Pinealon’s connection to sleep is less direct: its TPH1 upregulation feeds serotonin synthesis, which is a melatonin precursor, and the Huberman Lab discussion reported subjective REM sleep improvements with pulsed pinealon use. Epitalon’s PCAC review is filed under an insomnia indication, while pinealon has no regulatory sleep-related pathway.
Are either of these available through US compounding pharmacies?
As of mid-2026, neither is legally available through 503A compounding pharmacies in the United States. Epitalon’s status is pending the outcome of the July 2026 PCAC review, which could potentially open a compounding pathway if the committee rules favourably. Pinealon has no PCAC nomination and no pathway toward 503A compounding eligibility. Both are currently available only as research-use-only materials from peptide suppliers, not through licensed medical providers or pharmacies.
Where does the evidence for these compounds stand overall?
Both are preclinical research compounds with no completed, peer-reviewed human clinical trials. Epitalon has the stronger position with human cell-culture telomerase data, primate melatonin data, and some limited independent replication. Pinealon has compelling neuroprotection data in rodent models but no independent replication and no data beyond cell culture and animal studies. The 266-patient longevity study used the parent drug epithalamin (not synthetic epitalon), was not blinded or randomised, and has not been replicated independently. For both compounds, the research is scientifically interesting but falls short of the evidence standard required for regulatory approval in Western jurisdictions.
Epitalon and pinealon share a research programme and a proposed mechanism class, but they target different tissues, act through different molecular pathways and sit at different stages of evidence maturity.
Medical disclaimer: This comparison is for informational and educational purposes only and does not constitute medical advice. Neither epitalon nor pinealon is approved by the FDA, EMA, MHRA or TGA for any therapeutic indication. No completed human clinical trial has established the safety or efficacy of either compound. Consult a qualified healthcare professional before making any decisions related to your health.